



For Immediate Release

PATHEON TO BUILD PHARMACEUTICAL DEVELOPMENT CENTER IN BOURGOIN, FRANCE

RESEARCH TRIANGLE PARK, N.C. (January 21, 2010) – Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today it has begun construction of a new pharmaceutical development center at its existing manufacturing facility in Bourgoin-Jallieu, France. This new addition will enable the Bourgoin site to offer a full range of solid dose services as part of its Pharmaceutical Development Services (PDS) business.

“We currently provide our customers with solid dose Phase 3 and commercial supply from our facilities in North America. With this expansion we will offer the same services in Europe by the end of 2010,” said Wes Wheeler, Patheon’s CEO and President. “The investment reinforces our commitment to provide our customers with a full range of product development services – from pre-clinical through late phase stages, on to commercialization.”

The state-of-the-art facility has been designed for the supply of late-phase clinical trial tablet and capsule products, and will be capable of handling batch sizes up to 120 kg. It will consist of a new pilot plant and equipment designed to contain high potency products. Process trains will be scalable to commercial lines, offering clients the ability to produce Phase 3 and commercial product in the same location.

ABOUT PATHEON

Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Patheon’s services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.

Patheon, with an integrated development and manufacturing network of 11 facilities and eight development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

Contacts:

Wes Wheeler
President and Chief Executive Officer
Tel: (919) 226-3200
Email: wes.wheeler@patheon.com

Eric Evans
Chief Financial Officer
Tel: (919) 226-3204
Email: eric.evans@patheon.com

Wendy Wilson
Investor Relations
Tel: (919) 226-3313
Email: wendy.wilson@patheon.com

###